Superoxide Induced Inhibition of Death Receptor Signaling is Mediated Via Induced Expression of Apoptosis Inhibitory Protein CFLIP
Overview
Cell Biology
Endocrinology
Authors
Affiliations
The death inhibitory proteins, cFLIP and Bcl-2, canonically act at different steps to regulate receptor-mediated apoptosis in cancer cells. Here we report that pharmacological or genetic means to effect an increase in intracellular superoxide result in cFLIP upregulation. Interestingly, Bcl-2 overexpression is associated with a concomitant increase in cFLIP, and reducing superoxide sensitizes Bcl-2 overexpressing cancer cells to receptor-mediated apoptosis via downregulation of cFLIP. Moreover, inhibiting glycolytic flux overcomes apoptosis resistance by superoxide-dependent downregulation of cFLIP. Superoxide-induced upregulation of cFLIP is a function of enhanced transcription, as evidenced by increases in cFLIP promoter activity and mRNA abundance. The positive effect of superoxide on cFLIP is mediated through its reaction with nitric oxide to generate peroxynitrite. Corroborating these findings in cell lines, subjecting primary cells derived from lymphoma patients to glucose deprivation ex vivo, as a means to decrease superoxide, not only reduced cFLIP expression but also significantly enhanced death receptor sensitivity. Based on this novel mechanistic insight into the redox regulation of cancer cell fate, modulation of intracellular superoxide could have potential therapeutic implications in cancers in which these two death inhibitory proteins present a therapeutic challenge.
Balamurli G, Liew A, Tee W, Pervaiz S Redox Biol. 2024; 78:103441.
PMID: 39612910 PMC: 11629570. DOI: 10.1016/j.redox.2024.103441.
Antiproliferative Impact of Linagliptin on the Cervical Cancer Cell Line.
Muafaq Said A, Abdulla K, Ahmed N, Yasin Y Asian Pac J Cancer Prev. 2024; 25(9):3293-3300.
PMID: 39342609 PMC: 11700340. DOI: 10.31557/APJCP.2024.25.9.3293.
Sukocheva O, Neganova M, Aleksandrova Y, Burcher J, Chugunova E, Fan R Cell Commun Signal. 2024; 22(1):251.
PMID: 38698424 PMC: 11064425. DOI: 10.1186/s12964-024-01626-6.
Ren Y, Wang R, Weng S, Xu H, Zhang Y, Chen S Mol Cancer. 2023; 22(1):130.
PMID: 37563639 PMC: 10413697. DOI: 10.1186/s12943-023-01831-w.
Shahriari Felordi M, Alikhani M, Farzaneh Z, Alipour Choshali M, Ebrahimi M, Aboulkheyr Es H J Cell Mol Med. 2023; 27(17):2572-2582.
PMID: 37537749 PMC: 10468655. DOI: 10.1111/jcmm.17873.